Search | IOVS | ARVO Journals

View

Showing 1 – 14 of 14

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract March 2012

Emergency Room Ocular Diagnosis Study 2 (ERODS2)

Paul O. Phelps; Geoffrey Hill; Kara LaMattina; Michael Giovingo; Jeff Wongskhaluang; Diane Fiander; Richard M. Ahuja

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):1406. doi:

ARVO Annual Meeting Abstract March 2012

Intravitreal Bevacizumab In The Treatment Of Macular Edema Secondary To Central Retinal Vein Occlusion

Augustine R. Hong; Igor Bussel; John M. Roberts, Jr.; Geoffrey Hill; Richard M. Ahuja

Invest. Ophthalmol. Vis. Sci.. 2012; 53(14):916. doi:

ARVO Annual Meeting Abstract April 2011

PGY 4 Capsulorhexis Performance Metrics on the Sensimmer "Phaco Simulator" and During Phacoemulsification-A Paired Control Study

P P. Banerjee; Charles S. Bouchard; Philip Dray; Paul Bryar; Richard M. Ahuja; Deepak P. Edward

Invest. Ophthalmol. Vis. Sci.. 2011; 52(14):4715. doi:

ARVO Annual Meeting Abstract April 2010

Long Term Follow-Up of Intravitreous Bevacizumab (Avastin) for Neovascular Glaucoma Secondary to Proliferate Diabetic Retinopathy

T. D. Albright; K. C. LaMattina; J. M. Roberts; P. MacIntosh; A. Desai; R. M. Ahuja

Invest. Ophthalmol. Vis. Sci.. 2010; 51(13):4236. doi:

ARVO Annual Meeting Abstract April 2010

Intravitreal Pegaptanib Sodium in the Treatment of Patients With Stage 3a Coats’ Disease

A. P. Gupta; M. Ghadiali; E. Wandel; R. M. Ahuja

Invest. Ophthalmol. Vis. Sci.. 2010; 51(13):5116. doi:

ARVO Annual Meeting Abstract April 2010

Intravitreal Bevacizumab (Avastin) for Neovascular Glaucoma Secondary to Central Retinal Vein Occlusion (crvo)

T. Larson; K. C. LaMattina; J. Chelnis; E. Wandel; C. Mata; R. M. Ahuja

Invest. Ophthalmol. Vis. Sci.. 2010; 51(13):3579. doi:

ARVO Annual Meeting Abstract April 2009

Long Term Follow-up of Intravitreal Bevacizumab (avastin) for Neovascular Glaucoma

J. Rowe; J. V. Wongskhaluang; T. Larson; T. Albright; R. M. Ahuja

Invest. Ophthalmol. Vis. Sci.. 2009; 50(13):1374. doi:

ARVO Annual Meeting Abstract April 2009

Comparison of Sedimentation rates of Kenalog and Triesence

R. M. Ahuja; K. N. Becker; N. J. Pathak; A. Gupta; A. Pantazis; S. Swindler; N. Becker

Invest. Ophthalmol. Vis. Sci.. 2009; 50(13):6238. doi:

ARVO Annual Meeting Abstract May 2008

Efficacy of Intravitreal Bevacizumab (Avastin) in Patients With Proliferative Diabetic Retinopathy

P. L. Tsai; K. M. Riaz; K. K. Kamat; N. J. Pathak; J. A. Rowe; R. M. Ahuja

Invest. Ophthalmol. Vis. Sci.. 2008; 49(13):2736. doi:

ARVO Annual Meeting Abstract May 2008

Posterior Subtenon’s Triamcinolone Acetonide for the Treatment of Diabetic Macular Edema Refractory to Focal Macular Photocoagulation

K. Z. Danek; H. Patel; D. G. Reddy; D. Wyatt; R. M. Ahuja

Invest. Ophthalmol. Vis. Sci.. 2008; 49(13):2755. doi:

ARVO Annual Meeting Abstract May 2008

Effect of Intravitreous Injection of Bevacizumab on Systemic Blood Pressure

N. J. Pathak; P. L. Tsai; K. K. Kamat; K. M. Riaz; M. K. Eide; A. P. Gupta; R. M. Ahuja

Invest. Ophthalmol. Vis. Sci.. 2008; 49(13):5589. doi:

ARVO Annual Meeting Abstract May 2008

Intravitreal Bevacizumab (Avastin) in Patients With Neovascular Glaucoma

M. K. Eide; P. L. Tsai; N. J. Pathak; K. K. Kamat; K. M. Riaz; R. M. Ahuja

Invest. Ophthalmol. Vis. Sci.. 2008; 49(13):5590. doi:

ARVO Annual Meeting Abstract May 2007

Intravitreal Bevacizumab (Avastin) in Patients With Proliferative Diabetic Retinopathy

P. Tsai; K. K. Kamat; N. J. Pathak; K. Z. Danek; R. M. Ahuja

Invest. Ophthalmol. Vis. Sci.. 2007; 48(13):1419. doi:

ARVO Annual Meeting Abstract May 2007

Follow-Up After Bare Sclera Pterygium Excision and 0.10 ml of a 0.05 mg/ml of Preoperative Subconjunctival Mitomycin-C

E. B. Saucedo-Sanchez; A. Pantazis; L. Yang; M. K. Eide; P. B. Dray; R. M. Ahuja

Invest. Ophthalmol. Vis. Sci.. 2007; 48(13):5293. doi:

Advertisement